Laurus Labs gets EIR from USFDA for Unit 2 at Visakhapatnam

Laurus Labs Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 540222 | NSE: LAURUSLABS

23 Jan 2020 Evaluate

Laurus Labs has received an Establishment Inspection Report (EIR) (for the Pre-Approval Inspection) from US Food and Drug Administration (USFDA) for its Unit-2 (FDF&API integrated facility) located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.

The Pre-Approval Inspection (PAI) was carried out from November 04, 2019 to November 08, 2019.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Peers

Company Name	CMP
Sun Pharma. Inds.	1853.00
Dr. Reddys Labs.	1200.40
Cipla	1404.00
Lupin	2098.00
Zydus Lifesciences	1180.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.